Alvotech Sees 210% Increase in Product Revenue to $204.7 Million in H1 2025.

Alvotech reported a 210% increase in product revenue to $204.7 million in H1 2025, driven by expanded sales of their Humira and Stelara biosimilars. The company achieved an operating profit of $28.6 million and a net profit of $141.7 million ($0.50 per share), compared to a $153.5 million loss in the same period last year. Alvotech also made strategic acquisitions and partnerships to strengthen its position in the biosimilars market.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, reported robust financial results for the first six months of 2025. The company's product revenue surged by over 200% year-on-year to $204.7 million, driven by expanded sales of their biosimilar candidates, including Humira and Stelara. This significant growth contributed to an operating profit of $28.6 million and a net profit of $141.7 million ($0.50 per share), marking a substantial turnaround from the $153.5 million loss recorded in the same period last year [1].

The company's strong performance was also underpinned by strategic acquisitions and partnerships. Alvotech entered into two agreements with Advanz Pharma to expand commercial partnerships, covering four biosimilar candidates, and collaborated with Dr. Reddy’s Laboratories Ltd. to co-develop, manufacture, and commercialize AVT32, a biosimilar candidate to Keytruda® (pembrolizumab) [1]. Additionally, the company completed the acquisition of Xbrane’s R&D facilities in Sweden and Ivers-Lee Group in Switzerland, further bolstering its development capabilities and pipeline [1].

Alvotech’s cash position as of June 30, 2025, stood at $151.5 million, supported by robust operational performance and successful funding rounds. The company’s gross proceeds from a Swedish private placement were approximately SEK 789 million, and it entered into an amended term loan credit agreement to reduce interest expenses by $8.2 million in the first 12 months [1].

The company’s Chief Financial Officer, Linda Jónsdóttir, who replaced Joel Morales, highlighted the company's strategic initiatives and the potential for future growth. "The strong results from the first half of the year, with over 200% increase in product revenues year-on-year and the best quarter in our history in terms of operating cash flows, confirm our business momentum and the opportunities that lie ahead," said Robert Wessman, Chairman and CEO of Alvotech [1].

Alvotech's financial results reflect a company that is well-positioned to capitalize on the growing demand for biosimilar medicines. The company's strategic focus on expanding its pipeline and strengthening commercial partnerships indicates a commitment to long-term growth and operational scale.

References:
[1] https://investors.alvotech.com/news-releases/news-release-details/alvotech-reports-results-first-six-months-2025-and-provides